Switching from Mounjaro to Wegovy: Is It the Right Time to Switch?
Deciding when to move from Mounjaro to Wegovy depends on factors like rising costs, side effects, slowing progress, or availability.
The FreeStyle Libre 3 Plus is set to revolutionise glucose monitoring across the UK, with Abbott announcing its official replacement of previous FreeStyle Libre sensors. With improved accuracy, extended wear, and superior app integration, the FreeStyle Libre 3 Plus is not just an upgrade—it’s a complete game-changer in diabetes management.
This announcement signals a new era in Continuous Glucose Monitoring (CGM) technology, combining ease of use, better insights, and enhanced patient outcomes. Designed with user comfort and NHS cost-efficiency in mind, this next-generation sensor will soon become the default option for existing and new users across the country.
The FreeStyle Libre 3 Plus is a next-gen CGM system that offers real-time glucose readings directly to a smartphone every minute. Like its predecessors, it is factory-calibrated and requires no finger-prick calibration. However, what sets it apart are the refined features aimed at boosting accuracy, reducing discomfort, and improving long-term diabetes care.
Key highlights include:
This model retains the affordability and NHS reimbursement eligibility of the earlier FreeStyle Libre models, ensuring continued accessibility for users.

One of the core reasons for the shift is clinical accuracy. FreeStyle Libre 3 Plus offers better Mean Absolute Relative Difference (MARD) scores than earlier versions, which means readings are closer to true blood glucose values. This is critical for both insulin dosing and lifestyle decisions.
With a 15-day wear duration, users experience fewer sensor changes each month, reducing costs and interruptions. The new sensor uses advanced adhesive technology to provide a more secure yet skin-friendly experience for longer periods.
Unlike older models that required scanning, the Libre 3 Plus pushes glucose data automatically every minute to a user’s smartphone. This real-time insight allows for better glucose trend monitoring and reduces the chances of hypo- or hyperglycaemic events.
The introduction of a single standardised sensor simplifies logistics for the NHS and pharmacies. With fewer SKUs to manage, stock issues and prescribing errors are expected to drop significantly, improving continuity of care.

If you’re using the FreeStyle Libre 2, FreeStyle Libre 3, or the original Libre system, your prescriptions will gradually be updated to the Libre 3 Plus. You won’t need to take action—GP practices and pharmacies will handle the transition automatically unless you opt out for clinical reasons.
Newly diagnosed individuals or those moving to CGM for the first time will be started directly on the FreeStyle Libre 3 Plus, benefiting immediately from its advancements.

Receiving glucose updates every minute allows users to detect trends and act proactively, significantly reducing the risk of dangerous sugar fluctuations.
The Libre 3 Plus is Abbott’s smallest sensor yet, almost 70% smaller than Libre 2, sitting closer to the skin and allowing for more freedom of movement and less visibility under clothing.
Users continue to benefit from a needle-free experience, with no need for finger-prick calibration—especially beneficial for younger patients and those with needle aversions.
With Libre 3 Plus, data can be easily shared with caregivers, family members, or healthcare providers in real time, making remote monitoring more efficient for both Type 1 and Type 2 diabetes patients.
Most users will receive Libre 3 Plus sensors through their existing NHS prescriptions automatically. Check with your GP or diabetes nurse to confirm the timing of your switch.
Ensure your smartphone is updated and compatible with the FreeStyle LibreLink app. This is essential as the Libre 3 Plus no longer requires or supports separate readers—it’s app-exclusive.
While there’s no urgency to discard your current sensors, future refills will likely only include Libre 3 Plus versions. Abbott will continue providing support for the transition period.

The new sensor supports better alignment with NICE recommendations for CGM use in both Type 1 and selected Type 2 diabetes patients. The improved accuracy and real-time alerts are particularly useful in high-risk groups.
Libre 3 Plus integrates with LibreView, Abbott’s cloud-based platform, giving clinicians access to more detailed reports and trends. This helps them make more informed decisions during reviews or insulin adjustments.
By replacing older models with a superior yet cost-equivalent sensor, Abbott solidifies its position as the leading CGM provider in the UK. Competitors will likely struggle to match both the technical innovation and the broad NHS distribution model that FreeStyle Libre 3 Plus offers.
The replacement of FreeStyle Libre 2 with Libre 3 Plus is more than a product swap—it’s a technological leap that brings patients closer to real-time, accurate, and user-friendly diabetes care. For healthcare systems, it simplifies supply chains, reduces cost variability, and improves standardisation.
For patients, it’s a future of fewer finger pricks, better control, and more confidence.
Stay informed. Speak to your GP or diabetes nurse today about the transition to FreeStyle Libre 3 Plus.
Yes. Eligible patients can access FreeStyle Libre 3 Plus via NHS prescriptions just like the previous versions, provided they meet the criteria set by local NHS trusts.
No. Libre 3 Plus is not compatible with handheld readers used in previous models. You must use the FreeStyle LibreLink app to access your data.
Yes. The sensor is water-resistant and can be worn while showering, swimming, or exercising, making it suitable for active lifestyles.
The MARD score for Libre 3 Plus is lower (meaning more accurate) than Libre 2, especially in critical glucose ranges, according to recent studies cited by Abbott.
Yes. Eligible patients can access FreeStyle Libre 3 Plus via NHS prescriptions just like the previous versions, provided they meet the criteria set by local NHS trusts.
No. Libre 3 Plus is not compatible with handheld readers used in previous models. You must use the FreeStyle LibreLink app to access your data.
Yes. The sensor is water-resistant and can be worn while showering, swimming, or exercising, making it suitable for active lifestyles.
The MARD score for Libre 3 Plus is lower (meaning more accurate) than Libre 2, especially in critical glucose ranges, according to recent studies cited by Abbott.
Medically reviewed by
Superintendent Pharmacist
Deciding when to move from Mounjaro to Wegovy depends on factors like rising costs, side effects, slowing progress, or availability.
Losing weight can often feel like a long road, especially when progress slows down despite your best efforts.
Is hair loss a common side effect of Mounjaro? Yes. Although it’s caused by weight loss – not the medication. Here’s why it happens, and how to manage hair loss without derailing your progress.
Erectile Dysfunction (ED) is becoming an increasingly common issue among men in the UK.
Erectile dysfunction (ED) affects millions of men across the UK and globally, yet it’s a condition surrounded by silence and stigma.
Mounjaro is a new generation weight loss medication gaining attention for its dual-action benefits.